| Sep 1, 2021 | LEXEO Therapeutics | $100.0M Series B | Daniel Saul Sundheim, Joy Ghosh | Omega Funds, Alexandria Venture Investments, CAM Capital, Gray's Creek Capital Partners, Invus, Janus Henderson Investors, Laurion Capital Management, Longitude Capital, PBM Capital, Verition Fund Management, Woodline Partners |
| Mar 22, 2021 | Aura Biosciences | $80.0M Other Equity | Karan Takhar, Surveyor Capital | Adage Capital Management, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Medicxi, Rock Springs Capital, Velosity Capital, Joel Jean Mairet |
| Jan 1, 2021 | LEXEO Therapeutics | $85.0M Series A | Omega Funds, Sandip Agarwala | Alexandria Venture Investments, Alzheimer's Drug Discovery Foundation, Invus, Janus Henderson Investors, Mette Kirstine Agger, PBM Capital, Woodline Partners |
| Dec 1, 2020 | Reneo Pharmaceuticals | $95.0M Series B | Abingworth, Ken Harrison | Generation Ventures, Ed Mathers, RiverVest, Aisling Capital, Amzak Health, Khosla Ventures, New Enterprise Associates, Pappas Capital, Niall O'Donnell, Rock Springs Capital |
| Jul 1, 2020 | VarmX | $36.0M Series B | INKEF Capital, Guillem Laporta, CFA | Atlas Venture, Endeavor Venture Funds, EQT Life Sciences, Qima Ventures, RTW Investments, Oskar Slotboom, InnovationQuarter, John de Koning, Casper Breum |
| May 1, 2020 | Amplyx Pharmaceuticals | $53.0M Series C | Sofinnova Ventures | Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, 3x5 Partners, Adage Capital Management, Arix Bioscience, BioMed Ventures, Pappas Capital, Pfizer, RiverVest Venture Partners |
| Jun 26, 2019 | SANIFIT | $82.1M Other Equity / Series D | Marcelino Armenter | Guy Paul Nohra, Andera Partners, Damià Tormo, Forbion, HealthEquity, Ysios Capital |
| May 1, 2019 | Reneo Pharmaceuticals | $50.0M Series A | New Enterprise Associates | Generation Ventures, Ed Mathers, RiverVest, Sofinnova Investments, Johan Kördel, Art Pappas, Niall O'Donnell |
| Apr 2, 2019 | Aura Biosciences | $40.0M Series D | Giovanni Mariggi | Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Ysios Capital |
| Mar 1, 2019 | Imara | $63.0M Series B | Arix Bioscience, OrbiMed | Aisling Capital, Endeavor Venture Funds, Soffinova Partners, Ysios Capital, James Barrett, Alexandria Venture Investments, Bay City Capital, New Enterprise Associates, Matthew Hammond, Rock Springs Capital |
| Jan 3, 2019 | Tiburio Therapeutics | $31.0M Series A | — | Alexandria Venture Investments, Longitude Capital, New Enterprise Associates |
| Jan 4, 2018 | ENTEROME | $86.7M Debt / Series D | — | Paul Biondi, Ambroise Fayolle, Health for Life Capital, Nestl \u00e9 Health Science, Omnes Capital, Paolo Daniele Siviero |
| Dec 1, 2017 | Atox Bio | $30.0M Series F | Jonathan Tobin | Brandon Capital Partners, Terry Gould, Asahi Kasei, Becker Ventures, Integra Holdings, OrbiMed, SR One |
| Dec 1, 2017 | Aura Biosciences | $30.0M Series C | Arix Bioscience, Casper Breum | Forbion, Sanofi Ventures, Versant Ventures, Ysios Capital, Henri Termeer, Advent Life Sciences, Alexandria Venture Investments, Chiesi Ventures, Columbus Venture Partners, LI-COR Biosciences |
| Jul 1, 2017 | Amplyx Pharmaceuticals | $67.0M Series C | Anand Mehra | Abingworth, Deerfield Management, Frazier Healthcare Partners, Ed Mathers, New Enterprise Associates, RiverVest, Mark Chin, BioMed Ventures, Johan Kördel, Pappas Capital, RiverVest Venture Partners |
| Jul 1, 2017 | Trevi Therapeutics | $30.0M Series C | New Enterprise Associates | Highbury Group, Aperture Venture Partners, Mette Kirstine Agger, Otello Stampacchia, Eran Nadav |
| Mar 1, 2017 | Spero Therapeutics | $52.0M Series C | GV | Atlas Venture, Endeavor Venture Funds, FPV Fund, MPM Capital, SR One, Westlake Village BioPartners, Timothy A. Springer, MRL Ventures Fund, Osage University Partners, RA Capital Management, Rock Springs Capital, The Kraft Group |
| Jan 4, 2017 | scPharmaceuticals | $45.6M Series B | Jonathan Silverstein, Abhay Gandhi | 5AM Ventures |
| Aug 1, 2016 | Iconic Therapeutics | $10.0M Series C | Fares Zahir | MPM Capital, Cormorant Asset Management, Matthias Fehr, H.I.G. BioHealth Partners, Osage University Partners |
| Jul 25, 2016 | Vtesse, Inc. | $17.0M Series A Extension | — | Alexandria Venture Investments, Bay City Capital, David Mott |
| Apr 14, 2016 | Imara, Inc | $31.0M Series A | — | Alexandria Venture Investments, Bay City Capital, New Enterprise Associates |
| Apr 1, 2016 | ENTEROME | $16.0M Series C | Seventure Partners, Lundbeckfond Ventures | Edward Van Wezel, Forbion, Novartis Venture Fund, Greg Behar |
| Feb 1, 2016 | Spero Therapeutics | $30.0M Series B | — | Atlas Venture, SR One, Elliott Sigal, Timothy A. Springer, MRL Ventures Fund, Partners Innovation Fund, The Kraft Group |
| Sep 9, 2015 | Biom'Up | $34.9M Series C | — | Laurent Higueret, Euroainvest, Karl Nagler, InnoBio, l'Améliane, Casper Breum, Merieux Equity Partners, OTC AM, Sham, Sofimac, Viveris Management |
| Sep 8, 2015 | SANIFIT | $40.9M Series C | Ysios Capital | Baxter Ventures, Forbion, La Caixa |
